MedTrace Logo

Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

NCT00017550 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-01-27

No results posted yet for this study

Summary

RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be effective treatment for myelodysplastic syndrome. It is not yet known whether immunosuppressive therapy is more effective than supportive care in treating myelodysplastic syndrome.

PURPOSE: Randomized phase II trial to compare the effectiveness of antithymocyte globulin with that of supportive care in treating patients who have myelodysplastic syndrome.

Conditions

Interventions

BIOLOGICAL

anti-thymocyte globulin

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Elizabeth C. Squiers, MD · Sangstat Medical Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Primary Completion
2003-11-30
Completion
2003-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00017550 on ClinicalTrials.gov